U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® …
ANN ARBOR, Mich., March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new …
U.S. FDA Approves Broad New Labels for NEXLETOL® and
Mar 22, 2024 · The U.S. approvals of NEXLIZET and NEXLETOL for cardiovascular risk reduction and LDL-C lowering were based on data generated from the CLEAR Outcomes trial, which was …
U.S. FDA Approves Broad New Labels for NEXLETOL and NEXLIZET to …
Apr 1, 2024 · The U.S. approvals of NEXLIZET and NEXLETOL for cardiovascular risk reduction and LDL-C lowering were based on data generated from the CLEAR Outcomes trial, which was …
NEXLIZET® & NEXLETOL® CLEAR Outcomes Trial Information
The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0.5% greater than placebo …
NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures …
Mar 22, 2024 · Esperion announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® …
NEXLIZET® & NEXLETOL® Patient Support Program & Resources
The bempedoic acid portion of NEXLIZET is used to lower the risk of heart attack and heart procedures, like stent placement or bypass surgery, in adults who are unable to take recommended statin …
FDA Expands Labels for Nexletol, Nexlizet to Prevent Heart ... - AJMC
Mar 22, 2024 · U.S. FDA approves broad new labels for Nexletol and Nexlizet to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of …
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and ...
Mar 22, 2024 · ANN ARBOR, Mich.--(BUSINESS WIRE)--Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label …
Nexlizet Patient Tips: 7 things you should know - Drugs.com
Nov 18, 2025 · The bempedoic acid component of Nexlizet also reduces the risk of a heart attack or revascularization procedures in statin-intolerant patients with or at risk for cardiovascular disease.
FDA approves broad new labels for Nexletol ( bempedoic acid) and ...
Apr 2, 2024 · FDA approves broad new labels for Nexletol ( bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) to prevent heart attacks and cardiovascular procedures in both primary and …